SCHEDULE: RA Capital Reduces Stake in Werewolf Therapeutics

RA Capital Management has disclosed a reduction in its beneficial ownership of Werewolf Therapeutics common stock through a series of open market sales.

Summary

• RA Capital Management, L.P. and associated entities reported a reduction in their holdings of Werewolf Therapeutics, Inc. common stock.
• The reporting persons now beneficially own 5,138,703 shares, representing approximately 10.6% of the outstanding common stock.
• The reduction in percentage ownership is attributed to both recent open market sales and changes in the issuer's total outstanding share count.
• Sales occurred between June 9, 2026, and June 15, 2026, at prices ranging from $0.36 to $0.4129 per share.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative signal, as the reduction of a significant stake by a specialized healthcare investment firm often suggests a lack of conviction in the immediate clinical or financial prospects of the issuer.

Positives

• The filing provides transparency regarding the investment firm's ongoing portfolio management activities.

Negatives

• The divestment by a significant institutional shareholder may be perceived as a lack of confidence in the near-term upside of the issuer.
• The shares were sold at a low price point, reflecting significant downward pressure on the stock's valuation.

Risks

• Continued selling pressure from major institutional holders could further depress the share price.
• The issuer's low share price may impact its ability to raise capital or maintain listing requirements.

Future Outlook

No specific forward-looking guidance regarding the issuer's business operations is provided in this filing.

Industry Context

StockSavvy.ai notes that institutional divestment in small-cap biotechnology firms often signals a rebalancing of risk or a shift in investment thesis, particularly when the stock is trading at low valuations.

Comparison to Industry Standards

• The divestment follows standard regulatory disclosure requirements for institutional investors holding over 5% of a public company.
• The price range of $0.36-$0.41 per share is consistent with the current market valuation of many early-stage clinical biotech companies.

Legal Proceedings

• None reported.

Related Party Transactions

• The filing discloses the relationship between RA Capital Management, the Fund, and the Nexus Fund II as part of the reporting group.

Stakeholder Impact

• Shareholders may experience increased volatility due to the institutional selling activity.
• The reduction in ownership may signal to the market that the firm is reducing its exposure to the issuer.

Next Steps

• Continued monitoring of future Form 4 or Schedule 13D filings to determine if RA Capital intends to further reduce or exit its position.

Key Dates

Recommendation

The active divestment by a major institutional investor, combined with the low share price, suggests that the market is currently pricing in significant risk, making this a cautious environment for retail investors.

Keywords

Werewolf Therapeutics, RA Capital Management, Schedule 13D, Biotech, Institutional Ownership, Divestment